KD Logo

Potential Price Increase for Halozyme Therapeutics Inc. (HALO) After Recent Insider Activity

In a filing, Halozyme Therapeutics Inc. revealed its PRESIDENT AND CEO Torley Helen unloaded Company’s shares for reported $0.59 million on Sep 12 ’24. In the deal valued at $59.20 per share,10,000 shares were sold. As a result of this transaction, Torley Helen now holds 676,744 shares worth roughly $42.57 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, Torley Helen sold 10,000 shares, generating $590,890 in total proceeds. Upon selling the shares at $59.09, the PRESIDENT AND CEO now owns 676,744 shares.

Before that, Torley Helen sold 10,000 shares. Halozyme Therapeutics Inc. shares valued at $590,870 were divested by the PRESIDENT AND CEO at a price of $59.09 per share. As a result of the transaction, Torley Helen now holds 676,744 shares, worth roughly $42.57 million.

Piper Sandler downgraded its Halozyme Therapeutics Inc. [HALO] rating to a Neutral from a an Overweight in a research note published on June 07, 2024; the price target was increased to $51 from $48. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in late February with a ‘”an Outperform”‘ rating. H.C. Wainwright began covering HALO with “Buy” recommendation on July 24, 2023. Goldman revised its rating on July 24, 2023. It rated HALO as “a Neutral” which previously was an “a Buy”.

Price Performance Review of HALO

On Monday, Halozyme Therapeutics Inc. [NASDAQ:HALO] saw its stock jump 0.98% to $62.91. Over the last five days, the stock has gained 6.20%. Halozyme Therapeutics Inc. shares have risen nearly 70.21% since the year began. Nevertheless, the stocks have risen 55.26% over the past one year. While a 52-week high of $65.53 was reached on 08/29/24, a 52-week low of $32.83 was recorded on 02/05/24. SMA at 50 days reached $57.55, while 200 days put it at $44.95.

Levels Of Support And Resistance For HALO Stock

The 24-hour chart illustrates a support level at 62.50, which if violated will result in even more drops to 62.08. On the upside, there is a resistance level at 63.39. A further resistance level may holdings at 63.86. The Relative Strength Index (RSI) on the 14-day chart is 62.57, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.31, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 37.78%. Stochastics %K at 47.92% indicates the stock is a holding.

How much short interest is there in Halozyme Therapeutics Inc.?

A steep rise in short interest was recorded in Halozyme Therapeutics Inc. stocks on 2024-08-30, growing by 1.09 million shares to a total of 10.04 million shares. Yahoo Finance data shows the prior-month short interest on 2024-07-31 was 8.95 million shares. There was a rise of 10.9%, which implies that there is a positive sentiment for the stock.

Most Popular